Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it ...

Recursion Pharmaceuticals' AI-driven Recursion OS platform shows strong potential but has yet to demonstrate a clear competitive edge. Read more on RXRX stock here.

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $117.5 million in its first quarter. The Salt Lake City-based company said it had a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 ...

Staff at Salt Lake City-based techbio company Recursion recently heard from Jenny and Tim Jones about their challenging ...